This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Obama-Proof: Pfizer, Bristol-Myers and Teva

TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.

When President Barack Obama proposed offering health care coverage to all Americans, the industry bristled and investors cringed.

But some drugmakers will gain even if the president's plan erodes profits by lowering prices. Pfizer (PFE), Bristol-Myers Squibb (BMY) and Teva Pharmaceuticals (TEVA) are three of them. Recommended as "buy" by TheStreet.com Ratings, the companies offer products and possess sound businesses that investors can be confident in.

TheStreet.com Ratings

Pfizer: Pfizer is an industry leader that has an impressive line-up of well-known pharmaceuticals, such as the cardiovascular drug Lipitor, with revenue of $2.7 billion in the first quarter, and Celebrex, an arthritis medication. With the addition of Wyeth (WYE), Pfizer will become even bigger and more stable.

Wyeth brings a mix of blockbuster over-the-counter products such as Advil, ChapStick and Centrum, in addition to big-name pharmaceuticals like Enbrel and Effexor, which account for 28% of revenue, helping to diversify Pfizer.

Due to an adjusted beta of 0.73 and a sensible debt-to-equity ratio of 0.14, Pfizer benefits from low volatility and moderate leverage. Explosive gains will be elusive, but stability is a big advantage.

Pfizer's stock has lagged in performance this year, dropping 14%, leading to a price-to-earnings ratio of 7.8, below the industry average of 16.2, suggesting a large undervaluation and a good buying opportunity.

Lastly, Pfizer pays out a robust 4.2% dividend.

Bristol-Myers Squibb: Bristol-Myers boasts a return on equity of 46%, underpinned by products such as Abilify and Plavix, which combined to represent 38% of last year's revenue. That can also be cause for alarm since the company is vulnerable to decreases in sales when patents run out.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs